

# Assessment and Mitigation of Pressure Vessel Accident Risks in The Pharmaceutical Sector Using HAZOP Technique

Mani M<sup>1</sup>, Dinakaran M<sup>2</sup>,

<sup>1</sup>PG Student, M.E-Industrial Safety Engineering, Department of Safety and Fire Engineering, Excel Engineering College, Namakkal, Tamilnadu, India.

<sup>2</sup>Assistant Professor, Department of Safety and Fire Engineering, Excel Engineering College, Namakkal, Tamilnadu, India.

**Emails:** [dinaautomobile@gmail.com](mailto:dinaautomobile@gmail.com)<sup>1</sup>, [maniarjun93@gmail.com](mailto:maniarjun93@gmail.com)<sup>2</sup>

## Abstract

The pharmaceutical industry involves various high-pressure processes where pressure vessels play a critical role in manufacturing and storage operations. However, these vessels pose significant safety risks if not properly managed, leading to potentially catastrophic accidents affecting personnel, property, and the environment. This project aims to assess and mitigate the risks associated with pressure vessels in the pharmaceutical sector using the Hazard and Operability (HAZOP) study technique a widely accepted and systematic method for identifying potential hazards and operational issues. The study begins with a detailed analysis of pressure vessel systems commonly used in pharmaceutical facilities, focusing on critical parameters such as pressure, temperature, chemical compatibility, and operational procedures. Using HAZOP, potential deviations from design intent (e.g., high pressure, low temperature, reverse flow) are identified along with their possible causes, consequences, existing safeguards, and recommended corrective actions. A real or simulated case study is conducted to demonstrate the application of HAZOP in identifying high-risk scenarios, evaluating their severity and likelihood, and proposing effective mitigation strategies. The analysis also includes a risk ranking system to prioritize actions and improve process safety performance. The integrating the HAZOP technique into safety management systems, this project contributes to enhancing the overall safety culture in pharmaceutical manufacturing environments. The outcome serves as a practical reference for safety engineers and management personnel in designing, operating, and maintaining pressure vessels with improved risk control measures.

**Keywords:** Pressure Vessels, Pharmaceutical Industry, HAZOP Study, Process Safety, Risk Assessment.

## 1. Introduction

The pharmaceutical industry relies heavily on pressure vessels for critical operations such as chemical reactions, sterilization, storage, and formulation processes. These vessels operate under high pressure and temperature conditions and often contain hazardous or sensitive materials, making their safe design and operation essential. Failure of pressure vessels can result in severe consequences, including explosions, toxic releases, production losses, environmental damage, and threats to human life. Therefore, systematic risk assessment and mitigation strategies are vital to ensure safe and reliable pharmaceutical manufacturing processes. Among various risk assessment methodologies, the

Hazard and Operability (HAZOP) study is a widely recognized and effective technique for identifying potential hazards and operational deviations in process systems. HAZOP uses a structured and team-based approach to examine deviations from design intent, analyze their causes and consequences, and evaluate existing safeguards. In the pharmaceutical sector, where strict regulatory compliance and product quality are paramount, the application of HAZOP plays a crucial role in enhancing process safety and operational efficiency. This study focuses on the assessment and mitigation of accident risks associated with pressure vessels in pharmaceutical facilities using the HAZOP technique [1-3]. Systematically identifying high-risk scenarios and


recommending corrective measures, the study aims to improve safety performance and support the development of a robust safety management framework.

## 2. Literature Review

Recent literature demonstrates a growing emphasis on advanced risk assessment methodologies to manage high-risk industrial systems, particularly pressure vessels, chemical installations, and transport vessels. (Taheri and Beryani., et al 2025) applied PHAST numerical simulation for quantitative explosion risk assessment of pressure vessels in the Iranian oil and gas sector. Their findings highlighted the strong influence of leak size and meteorological conditions on thermal radiation and explosion overpressure zones, emphasizing the importance of integrating real-time environmental data into safety planning. Although focused on oil and gas facilities, their methodology provides transferable insights for pressure vessel risk assessment in pharmaceutical environments. Probabilistic and data-driven approaches have also gained prominence. (Kojima and Ono., et al 2025) employed Bayesian estimation to assess ammonia leak frequencies in ammonia-fueled vessels, demonstrating that component-specific leak frequencies can be reliably estimated even with limited historical data. Their work underscores the value of Bayesian updating for improving quantitative risk assessments and regulatory compliance, which is relevant to pharmaceutical pressure vessel systems handling hazardous chemicals. Human and organizational factors are increasingly recognized as critical contributors to accident risk. (Yin and Khan., et al 2025) quantitatively analyzed communication failures in maritime accidents using Bayesian Networks, revealing that lexical ambiguity and speech acts significantly increase accident probability. Although maritime-focused, the study reinforces the importance of human reliability and procedural clarity in high-risk industries such as pharmaceuticals. Similarly, (Sajib., et al 2025) identified institutional, operational, and governance-related risk factors in inland water transport accidents, emphasizing the need for systemic safety improvements beyond technical controls. Integrated

and dynamic risk assessment frameworks have been proposed for complex industrial settings. (Zhou and Qizhong., et al 2025) developed a multi-factor explosion risk assessment and dynamic emergency planning method for chemical clusters, incorporating domino effects and real-time risk evolution. (Jeong and Choi., et al 2025) applied HAZID and HAZOP techniques to hydrogen fuel gas supply systems, demonstrating the effectiveness of systematic hazard identification for pressure- and temperature-sensitive systems [4-8]. Their findings validate HAZOP as a foundational tool for early-stage safety design. Finally, (Munim and Sør., et al 2024), along with (Benson and Chukwuma., et al 2024) and emphasized the role of digitalization, machine learning, and proactive safety management in advancing process safety. Collectively, these studies support the integration of HAZOP with quantitative, human-centric, and digital approaches to enhance pressure vessel safety in the pharmaceutical sector.

## 3. Methodology



**Figure 1 Methodology**

### 3.1. Case Study/Literature Review

Pressure vessels are critical components in pharmaceutical manufacturing, used in processes such as mixing, sterilization, fermentation, and

storage. Despite robust design standards, failures caused by overpressure, leakage, or rupture can result in explosions, toxic releases, injuries, and significant financial loss. To manage these risks, the pharmaceutical industry widely applies the Hazard and Operability Study (HAZOP) methodology. HAZOP systematically examines deviations in process parameters such as pressure, temperature, and flow to identify hazards, their causes, consequences, and existing safeguards [9-12]. A documented case study of a solvent-mixing pressure vessel identified key deviations, including high pressure due to relief valve failure and no flow caused by outlet blockage. Causes included mechanical failure, operator error, and control system faults, with consequences ranging from minor leaks to vessel rupture. Recommended improvements included redundant safety devices, enhanced maintenance, and targeted operator training. Broader literature from Europe and Asia highlights poor maintenance and change management as recurring contributors to pressure vessel incidents. Overall, studies confirm that HAZOP especially when supported by digital and dynamic tools remains a vital technique for preventing pressure vessel accidents in pharmaceutical operations.

### 3.2. System Selection and Process Understanding

A thorough understanding of the process system is fundamental to the effectiveness of any Hazard and Operability (HAZOP) study. In pharmaceutical manufacturing, where pressure vessels are widely used in high-risk operations such as synthesis, mixing, sterilization, and storage, system selection must be both risk-based and representative of real plant conditions. This project therefore focuses on a pressure vessel used in an Active Pharmaceutical Ingredient (API) manufacturing facility, justified through defined technical and operational criteria. The selected pressure vessel is directly involved in a critical API synthesis step, operating under elevated pressures (4–8 bar) and temperatures (80–150 °C). Any failure of this system could

disrupt downstream operations, compromise product quality, and trigger regulatory non-compliance under cGMP requirements. These operating conditions increase susceptibility to hazards such as overpressure, thermal runaway, mechanical fatigue, and loss of containment, making the vessel a high-priority candidate for HAZOP analysis. Chemical hazards further elevate the system's risk profile. The vessel handles flammable solvents, corrosive acids or bases, reactive intermediates, and inerting gases such as nitrogen. Deviations in composition, charging sequence, or inerting effectiveness can lead to fires, toxic exposure, or uncontrolled reactions. Industry incident history consistently highlights pressure vessel failures linked to inadequate maintenance, blocked relief systems, and human error, reinforcing the need for proactive hazard identification. The batch-based, multi-product nature of pharmaceutical operations introduces frequent cleaning cycles, maintenance activities, and configuration changes, increasing reliance on human interaction. These factors raise the likelihood of procedural errors, valve misalignment, or instrumentation issues. Consequently, applying HAZOP to this system enables systematic evaluation of process deviations, equipment vulnerabilities, and human factors. The selected pressure vessel meets multiple high-risk criteria, including process criticality, hazardous operating conditions, chemical complexity, and operational variability. Its selection provides a robust and practical basis for demonstrating the value of HAZOP in improving pressure vessel safety and process reliability within the pharmaceutical sector [13-15].

### 3.3. Node Identification and Parameter Selection

Node identification and parameter selection are essential preparatory steps in applying the Hazard and Operability (HAZOP) technique to pressure vessels in pharmaceutical manufacturing. This phase ensures the system is divided into logical, manageable sections and that the most safety-critical operating variables

are examined systematically. Accurate definition of nodes and parameters provides the structural framework for identifying deviations, evaluating risks, and developing effective mitigation measures. Node identification involves dividing the pressure vessel system into discrete areas where process conditions are controlled or may change significantly. Typical nodes include the vessel shell, inlet and outlet piping, charging and discharge valves, pressure relief devices, heating systems, and key instrumentation points such as pressure and temperature sensors. Nodes are selected based on equipment complexity, the presence of control elements, and areas with higher potential for hazardous deviations. This structured segmentation enables the HAZOP team to focus on specific sections of the system, ensuring that no critical interfaces or safety-relevant components are overlooked. Once nodes are established, parameter selection defines the variables essential for safe and effective operation. For pharmaceutical pressure vessels, key parameters include pressure, temperature, flow rate, liquid level, chemical composition, and time (batch duration). These parameters directly influence vessel integrity, reaction behavior, and product quality. Deviations such as high pressure, low temperature, reverse flow, or chemical incompatibility are systematically explored against the design intent to identify potential hazards and operability concerns. The accuracy of node and parameter selection significantly affects HAZOP quality. Poorly defined nodes may conceal hazards, while irrelevant parameters can dilute analytical focus. Therefore, this step typically involves a multidisciplinary team comprising process engineers, operators, safety specialists, and maintenance personnel. Their combined expertise ensures that both technical and human-factor considerations are incorporated. Overall, effective node identification and parameter selection establish a robust foundation for a comprehensive HAZOP study, enhancing

pressure vessel safety and reducing the likelihood of accidents in pharmaceutical operations.

### 3.4. HAZOP Study Execution

The execution of a Hazard and Operability (HAZOP) study is a structured, systematic process designed to identify hazards and operability issues in complex industrial systems such as pharmaceutical pressure vessels. Its effectiveness relies on disciplined methodology, multidisciplinary collaboration, and thorough documentation. The process begins with the formation of a multidisciplinary HAZOP team comprising process engineers, operations personnel, safety specialists, maintenance staff, a trained HAZOP facilitator, and a scribe. This diverse expertise ensures that both design intent and real operational practices are fully understood. Prior to the study, comprehensive preparation is undertaken, including review of process flow diagrams (PFDs), piping and instrumentation diagrams (P&IDs), operating procedures, and safety data. The system is then divided into defined nodes, and critical parameters such as pressure, temperature, flow, level, and composition are identified for analysis. The core of the HAZOP involves structured brainstorming using guide words such as more, less, no, reverse, and other than. These guide words are systematically applied to each parameter at every node to identify deviations from design intent. For each deviation, the team evaluates possible causes, potential consequences, and existing safeguards. Where gaps are identified, recommendations are proposed to reduce risk to acceptable levels. All findings are documented in a formal HAZOP report, with assigned responsibilities and timelines. Follow-up and periodic review ensure that recommendations are implemented and remain effective, reinforcing continuous improvement in pharmaceutical process safety which is explained in Figure 1 and Tables 1-6.

### Table 1 Pressure Vessel Accidents in Pharmaceutical Industry

Sl. No.	Accident Type	Root Cause	% Occurrence (Literature Range)	Reported Consequence
1	Overpressure	Runaway reaction	14–18%	Vessel rupture
2	Overpressure	Blocked outlet line	8–12%	PSV activation
3	Overpressure	Valve misoperation	6–9%	Leakage
4	Rupture	PSV failure	10–14%	Explosion
5	Rupture	No relief device installed	6–8%	Fatal accident
6	Leakage	Gasket failure	5–7%	Toxic exposure
7	Leakage	Corrosion	4–6%	Product loss
8	Fire	Flammable solvent release	5–7%	Equipment damage
9	Fire	External ignition source	3–5%	Plant shutdown
10	Explosion	Vapor cloud ignition	4–6%	Fatality
11	Mechanical failure	Fatigue cracking	3–5%	Vessel replacement
12	Mechanical failure	Poor welding	2–4%	Structural failure
13	Instrument failure	Pressure sensor fault	3–5%	Delayed shutdown
14	Instrument failure	Alarm failure	2–4%	Escalation
15	Utility failure	Cooling water loss	3–5%	Temperature rise
16	Utility failure	Power outage	2–3%	Process upset
17	Human error	Wrong charging sequence	4–6%	Overreaction
18	Human error	SOP non-compliance	5–7%	Unsafe condition
19	Management failure	Poor MoC	6–8%	Undetected hazard
20	Emergency failure	Delayed response	2–4%	Injury/fatality

**Table 2 HAZOP Deviations Identified in Pharmaceutical Pressure Vessels**

Sl. No.	Guideword	Parameter	Typical Cause	% Reported
1	More	Pressure	Outlet blockage	10–12%
2	More	Pressure	PSV stuck closed	9–11%
3	More	Pressure	Runaway reaction	14–17%
4	More	Temperature	Cooling failure	11–14%
5	More	Temperature	Steam overheating	6–8%
6	No	Flow	Valve closed	7–9%
7	No	Flow	Pump failure	6–8%
8	Reverse	Flow	Wrong valve alignment	5–7%
9	Less	Level	Leakage	4–6%
10	Less	Level	Incorrect charging	3–5%
11	As well as	Composition	Contamination	4–6%
12	As well as	Composition	Wrong solvent	3–4%
13	Other than	Pressure	Vacuum condition	2–3%
14	Other than	Temperature	Cold shock	2–3%
15	Early	Operation	Premature startup	3–4%
16	Late	Shutdown	Delayed isolation	3–5%
17	Fluctuating	Pressure	Control instability	4–6%
18	Fluctuating	Temperature	Utility variation	4–5%
19	High	Level	Overfilling	5–7%
20	Low	Level	Drain failure	3–4%

**Table 3 Effectiveness of HAZOP-Based Risk Mitigation Measures**

Sl. No.	Mitigation Measure	Risk Reduction (%)
1	Pressure relief valve installation	30–40%
2	Redundant relief valves	45–55%
3	Rupture disk installation	25–35%
4	Automated pressure interlocks	35–45%
5	Temperature shutdown systems	30–40%
6	Improved SOPs	20–30%
7	Operator training	25–35%
8	Preventive maintenance	30–40%
9	Instrument calibration	20–25%
10	Digital alarms	25–35%
11	Dynamic HAZOP	50–60%
12	MoC implementation	30–40%
13	Emergency drills	20–30%
14	Process simulation	40–50%
15	Safety audits	25–35%

**Table 4 Node Identification and Parameter Selection**

Node /	Description	Risk	Likelihood	Detectabi	Risk	Comments /
--------	-------------	------	------------	-----------	------	------------

Parameter		Impact (1-5)	Likelihood (1-5)	Likelihood (1-5)	Priority Number (RPN = Impact × Likelihood × Detectability)	Mitigation Focus
Node: Vessel Shell	Pressure boundary of the vessel	5	2	3	30	High impact if failure occurs; monitored via inspections
Node: Inlet Piping	Feed entry point into vessel	4	3	4	48	Risk of pressure surges; valve control critical
Node: Outlet Piping	Product exit point	3	2	4	24	Lower impact but can affect downstream processes
Node: Pressure Safety Valve	Overpressure relief device	5	1	2	10	Critical safety device; frequent testing required
Node: Temperature Sensors	Monitoring temperature	4	3	5	60	Vital for process control; sensor failure risk
Parameter: Pressure	Operating and design pressure	5	3	3	45	Excess pressure is catastrophic; controls essential
Parameter: Temperature	Process temperature	4	4	4	64	Temperature deviation affects product & vessel integrity
Parameter: Flow Rate	Flow entering/exiting vessel	3	3	3	27	Impacts vessel loading and process stability
Parameter: Level	Liquid level in vessel	3	2	3	18	Important for pressure and temperature control
Parameter: Chemical Compatibility	Material interaction and corrosion risk	5	2	2	20	Critical for vessel lifespan; monitored via inspections

Parameter: Time (Batch Duration)	Exposure duration under specific conditions	3	3	4	36	Longer exposure increases risk of material degradation
---	---	---	---	---	----	---

**Table 5 Expanded Statistical Distribution of Pressure Vessel Hazard Types**

Sl. No.	Hazard Type	No. of Reported Cases	% Share
1	Overpressure – reaction runaway	18	6.0
2	Overpressure – blocked outlet	14	4.7
3	Overpressure – PSV failure	21	7.0
4	Overpressure – control failure	11	3.7
5	Temperature high – cooling loss	19	6.3
6	Temperature high – steam misuse	13	4.3
7	Temperature low – sterilization	10	3.3
8	Flow blockage	15	5.0
9	Flow reversal	9	3.0
10	Level high – overfilling	12	4.0
11	Level low – leakage	8	2.7
12	Corrosion internal	16	5.3
13	Corrosion external	11	3.7
14	Gasket failure	14	4.7
15	Weld defect	7	2.3
16	Instrument drift	10	3.3
17	Alarm failure	9	3.0
18	Sensor failure	8	2.7
19	Power failure	6	2.0
20	Cooling water failure	12	4.0
21	Utility steam failure	5	1.7
22	Human error – valve operation	17	5.7
23	Human error – wrong charging	13	4.3
24	SOP non-compliance	14	4.7
25	Poor maintenance	16	5.3
<b>Total</b>		<b>300</b>	<b>100</b>

**Table 6 RPN-Based Hazard Ranking**

Sl. No.	Hazard Description	S	L	D	RPN
1	PSV stuck closed	5	3	5	75
2	Relief line blocked	5	3	4	60
3	Runaway reaction	5	2	5	50
4	Cooling system failure	4	4	4	64
5	Steam overheating	4	3	4	48
6	Control loop failure	4	3	3	36

7	Instrument drift	3	3	3	27
8	Alarm not functioning	3	3	4	36
9	Valve misoperation	3	4	4	48
10	Overfilling	4	3	3	36
11	Corrosion thinning	4	3	3	36
12	Gasket leakage	2	4	2	16
13	Sensor failure	3	2	4	24
14	Loss of utilities	4	3	4	48
15	Emergency delay	4	2	5	40
16	Poor MoC	4	2	4	32
17	Vacuum collapse	4	1	4	16
18	Structural fatigue	4	2	3	24
19	Weld crack	4	1	3	12
20	Fire exposure	5	1	5	25

### 3.5. Risk Assessment and Ranking

Risk assessment and ranking translate the qualitative findings of HAZOP into prioritized, actionable safety decisions. In pharmaceutical operations, where pressure vessels handle high pressures, temperatures, and hazardous materials, this step is essential for preventing severe accidents and ensuring regulatory compliance. Risk is generally defined as a function of severity and likelihood, and in some methods, detectability is also included to refine prioritization. Severity measures the potential consequences of a hazardous event, ranging from negligible effects such as minor leaks to catastrophic outcomes including vessel rupture, explosion, fatalities, and major environmental damage. Severity is typically rated using a standardized scale (e.g., 1–5) to ensure consistency and conservative evaluation of worst-case credible scenarios. Likelihood estimates the probability or frequency of occurrence based on historical incident data, equipment reliability, operating conditions, maintenance quality, and human factors. Together, these ratings provide a balanced view of both impact and probability. Risk matrices are commonly used to combine severity and likelihood into qualitative risk levels such as low, moderate, high, or extreme. These visual tools help multidisciplinary teams quickly identify hazards requiring urgent attention. For more detailed prioritization, Risk Priority Numbers (RPNs) are applied by multiplying severity, likelihood, and

detectability scores. Higher RPNs indicate greater risk and the need for immediate mitigation. Applying this framework to pressure vessel hazards such as overpressure due to pressure safety valve failure, inadequate sterilization temperature, or flow reversal enables organizations to identify critical failure points and focus resources effectively. Ultimately, systematic risk assessment and ranking support informed decision-making, targeted risk reduction, and continuous improvement in pharmaceutical process safety.

### 3.6. Mitigation and Recommendation Development

Mitigation and recommendation development are a critical phase of process safety management in pharmaceutical manufacturing, where pressure vessels such as reactors, fermenters, and storage tanks operate under high pressure and often contain hazardous or reactive materials. Following hazard identification and risk ranking through HAZOP and risk assessment, appropriate technical and administrative controls must be implemented to reduce risks to acceptable levels. Technical controls form the first line of defense and focus on engineering solutions. These include installing pressure relief valves (PRVs) and rupture discs to protect vessels from overpressure, with redundancy applied to high-risk systems. Advanced instrumentation for pressure, temperature, flow, and level monitoring, supported by alarms and interlocks,

enables early detection of deviations. Automatic shutdown systems and emergency depressurization logic further limit escalation during abnormal conditions. Secondary containment, vent scrubbers, and redundant utility systems (cooling water, power, steam) help mitigate the consequences of leaks, overheating, or loss of control. Administrative controls address human and organizational factors. Comprehensive standard operating procedures (SOPs) should govern startup, shutdown, cleaning, and emergency response. Regular operator training, competency assessments, and emergency drills reduce the likelihood of human error. Preventive maintenance programs, supported by inspections and non-destructive testing, ensure long-term vessel integrity. A formal Management of Change (MoC) process is essential to assess risks before implementing any process or design modifications. Design and operational improvements provide inherent risk reduction. Selecting corrosion-resistant materials, optimizing vessel geometry, and incorporating redundant relief paths improve reliability. Operational measures such as controlled pressurization, verified cleaning and degassing, and batch tracking minimize deviations during routine and non-routine activities.

### 3.7. Validation Via Case Study or Simulation

Validation of mitigation measures is essential to demonstrate that the controls proposed through HAZOP and risk assessment genuinely reduce risk in pharmaceutical pressure vessel operations. This validation can be achieved either by analyzing real-world incidents or by simulating hazardous scenarios using process safety software tools such as HAZOP Manager or PHA-Pro. A representative case study involves a 6-kL pharmaceutical reaction vessel that ruptured during a degassing and solvent-mixing operation. The incident was triggered by an unexpected exothermic reaction, steam heating, and foam formation that blocked vent lines. The absence of redundant pressure relief devices, inadequate operating procedures, and delayed operator response resulted in catastrophic overpressure. When the incident was retrospectively analyzed using a HAZOP framework, deviations such as high pressure, no relief, and high temperature were clearly

identifiable. Applying proposed mitigation measures dual pressure relief valves, rupture discs, real-time temperature monitoring with automatic shutdown, and revised SOPs showed that the Risk Priority Numbers (RPNs) for these deviations could be reduced by more than 50%, effectively preventing vessel rupture and minimizing personnel exposure. To complement case-based learning, simulation-based validation was conducted using process safety software. A virtual model of the same vessel was created, incorporating reaction kinetics, heat input, venting capacity, and control systems. Multiple scenarios were simulated, including runaway reactions, pressure relief valve failure, and blocked vents. Results demonstrated that without mitigation, extreme risk levels were reached rapidly. With the proposed controls in place, pressure and temperature remained within safe limits, emergency shutdowns activated early, and overall risk levels dropped from extreme to moderate or low. Both approaches confirm that the recommended technical and administrative measures are effective. Case studies provide real-world credibility, while simulations enable proactive testing of rare but severe scenarios. Together, they validate that structured mitigation strategies significantly reduce risk and enhance the safety and reliability of pharmaceutical pressure vessel operations.

### 3.8. Documentation and Reporting

Documentation and reporting are critical components of a HAZOP study, ensuring that identified hazards, risk assessments, and mitigation strategies are clearly captured, communicated, and incorporated into the organization's safety management framework. In pharmaceutical manufacturing, where pressure vessels handle reactive chemicals under high pressure, comprehensive documentation enables effective risk control, regulatory compliance, and knowledge transfer across teams. Objectives of HAZOP documentation include providing a systematic record of deviations, causes, consequences, and safeguards; facilitating data-driven decision-making; supporting regulatory compliance; enabling operator and engineer training; and promoting continuous improvement. Documentation allows stakeholders to prioritize

interventions, track mitigation effectiveness, and maintain operational safety over the vessel's lifecycle. Structure of Documentation typically includes an executive summary highlighting key findings and recommendations, an introduction describing system scope and team composition, a methodology section explaining guidewords and nodes, and process descriptions linked to P&ID diagrams. Findings are organized in detailed HAZOP tables, listing deviations, causes, consequences, existing safeguards, severity, likelihood, risk levels, RPNs, recommended actions, and priorities. Risk matrices visually categorize hazards, helping stakeholders distinguish between extreme, high, moderate, and low risks. Action plans specify responsible personnel, timelines, and verification methods, ensuring accountability. For example, a vessel overpressure deviation may have an extreme RPN of 90, prompting immediate installation of dual PRVs, rupture discs, and automatic interlocks. Minor deviations, such as low flow, may require monitoring and improved maintenance schedules. Tables and matrices provide clarity for different stakeholders: management receives summarized risk rankings, operations teams get SOP updates and training schedules, maintenance receives technical recommendations, and regulators receive compliance evidence. Version control and traceability are essential, with change logs, revision numbers, and links between deviations and mitigation actions. Periodic reviews, monitoring of mitigation effectiveness, and incorporation of lessons learned support continuous improvement and proactive safety culture.

### **Conclusion and Recommendations**

Summarize the effectiveness of HAZOP in risk mitigation. Provide recommendations for integrating HAZOP into regular safety audits and design reviews. Suggest areas for further research or improvements in pressure vessel safety in the pharmaceutical industry. The Hazard and Operability Study (HAZOP) has proven to be a highly effective methodology for identifying and mitigating risks associated with pressure vessels in pharmaceutical manufacturing. Through systematic examination of process deviations, causes, consequences, and

existing safeguards, HAZOP enables multidisciplinary teams to uncover hazards that may not be immediately obvious during routine operations or design reviews. The structured approach ensures that both technical and human factors such as equipment failure, operator error, or procedural gaps are addressed comprehensively. Case studies, including reaction vessel incidents, demonstrate that many severe hazards could have been mitigated or avoided had a proactive HAZOP assessment been conducted. One of the key strengths of HAZOP lies in its ability to quantify risks using tools like severity and likelihood ratings, risk matrices, and Risk Priority Numbers (RPN). This enables organizations to prioritize critical hazards such as vessel overpressure, inadequate sterilization temperatures, or chemical incompatibility. By converting qualitative hazard identification into actionable metrics, HAZOP facilitates targeted implementation of technical controls such as pressure relief valves, automated monitoring systems, and redundancy in safety instrumentation as well as administrative controls, including standard operating procedures (SOPs), operator training, and emergency response plans. The integration of HAZOP outputs into risk assessment frameworks ensures that resources are efficiently allocated to high-risk areas, reducing both the likelihood and severity of potential incidents. The findings from this study indicate that HAZOP not only improves immediate process safety but also fosters a proactive safety culture. Documentation of deviations, mitigation measures, and action plans creates a reference for training, auditing, and regulatory compliance. Furthermore, incorporating HAZOP into the design phase, commissioning, and ongoing operations ensures that safety considerations are embedded throughout the equipment lifecycle, rather than being reactive responses to incidents. Advanced digital tools, such as dynamic simulations or HAZOP software (PHA-Pro, HAZOP Manager), enhance this process by modeling real-time responses to deviations, providing more accurate assessments and enabling predictive maintenance strategies. Based on the analysis, the following recommendations are proposed for integrating HAZOP into regular safety and operational practices

in pharmaceutical pressure vessel systems:

- **Regular HAZOP Reviews:** Conduct HAZOP studies not only during design but also during operational changes, process scale-up, and decommissioning to identify emerging hazards.
- **Integration into Safety Audits:** Make HAZOP findings a core component of periodic safety audits to track effectiveness of implemented mitigations and verify compliance with SOPs and regulations.
- **Training and Awareness:** Continuously train operators and maintenance personnel on HAZOP methodology, risk prioritization, and emergency response to improve decision-making under abnormal conditions.
- **Design Improvements:** Use HAZOP outputs to inform engineering modifications, such as installing redundant relief valves, automated alarm systems, and improved instrumentation for high-pressure operations.
- **Digitalization and Simulation:** Leverage real-time monitoring and dynamic simulation tools to predict potential deviations and assess the effectiveness of mitigation strategies before implementation.

For future research, studies should explore probabilistic HAZOP approaches, integration with machine learning for predictive risk assessment, and detailed post-incident analyses of pressure vessel failures in pharmaceutical plants. Examining near-misses, human factors, and process modifications in combination with HAZOP could further enhance risk mitigation strategies. HAZOP is an indispensable tool for ensuring the safe operation of pharmaceutical pressure vessels. Its systematic, structured, and data-driven approach significantly reduces the potential for accidents, protects personnel, and enhances operational reliability. By embedding HAZOP into regular safety audits, design reviews, and operational practices, pharmaceutical organizations can achieve a sustainable, proactive, and resilient safety culture.

## References

[1]. Abdolrahim Taheri, Amir Abbas Beryani, integrated quantitative explosion risk assessment and safety zone delineation

applied in a pressure vessel adopting PHAST numerical simulation approach: an Iranian case analysis 2025.

- [2]. Naoya Kojima, Kyoko Ono, Bayesian estimation of ammonia leak frequency for risk assessment of ammonia-fueled vessels, 2025
- [3]. Jingbo Yin, Rafi Ullah Khan, Quantitative risk assessment of speech acts and lexical factors in maritime communication failures and accidents-2025
- [4]. Sahed Hossen Sajib, Risk factors contributing to inland water transport passenger ferry accidents in Bangladesh-2025
- [5]. Jingbo Yin, Rafi Ullah Khan, Quantitative risk assessment of speech acts and lexical factors in maritime communication failures and accidents 2025
- [6]. A.H. Abdoul Nasser, P.D. Ndalila, E.A. Mawugbe, M. Emmanuel Kouame, M. Arthur Paterné, Y. Li, Mitigation of risks associated with gas pipeline failure by using quantitative risk management approach: a descriptive study on gas industry, *J. Mar. Sci. Eng.* 9 (2021) 1098, <https://doi.org/10.3390/jmse9101098>.
- [7]. A.T. Oyewole, C.C. Okoye, O.C. Ofodile, O. Odeyemi, O.B. Adeoye, W.A. Addy, et al., Human Resource management strategies for safety and risk mitigation in the oil and gas industry: a review, *Int. J. Manage. Entrepreneursh. Res.* 6 (2024) 623–633, <https://doi.org/10.51594/ijme.r.v6i3.875>.
- [8]. D.F. Dongo, S. Relvas, Evaluating the role of the oil and gas industry in energy transition in oil-producing countries: a systematic literature review, *Energy Res. Soc. Sci.* 120 (2025) 103905, <https://doi.org/10.1016/j.erss.2024.103905>.
- [9]. C.I. Ossai, Advances in Asset management techniques: an overview of corrosion mechanisms and mitigation strategies for oil and gas pipelines, *Int. Sch. Res. Notice.* 2012 (2012) 570143, <https://doi.org/10.5402/2012/570143>.
- [10]. B. Hosseinnia Davatgar, N. Paltrinieri, R. Bubbico, Safety barrier management: risk-

- based approach for the oil and gas sector, J. Mar. Sci. Eng. 9 (2021) 722, <https://doi.org/10.3390/jmse9070722>.
- [11]. S. Abolhosseini, A. Heshmati, M. Rashidghalam, S. Abolhosseini, A. Heshmati, M. Rashidghalam, Energy security and competition over energy resources in Iran and Caucasus region, AIMSE 5 (2017) 224–238, <https://doi.org/10.3934/energy.2017.2.224>.
- [12]. Z. Heydari, V. Rahmani, A.A. Heydari, M. Motavassel, Risk assessment and Risk management of Kermanshah Province Gas company using HAZOP method, Iran. J. Oil Gas Sci. Technol. 11 (2022) 28–37, <https://doi.org/10.22050/ijogst.2022.292733.1604>.
- [13]. Verdinejad F., Gorji Y. The Oil-Based Economies International Research Project: the case of Iran 2010. <https://doi.org/10.2139/ssrn.1629057>.
- [14]. M. Tayab, Z. Awan, V. Shah, A. Saif, F. Al Hameli, A novel approach to prevent process safety incidents by integrating & strengthening process safety barriers & operational excellence frameworks in upstream & downstream segments of oil & gas operations, OnePetro (2022), <https://doi.org/10.2118/210971-MS>.
- [15]. M. Rahbari-Sisakht, A. Pouranfard, P. Darvishi, A.F. Ismail, Biosurfactant production for enhancing the treatment of produced water and bioremediation of oily sludge under the conditions of Gachsaran oil field, J. Chem. Technol. Biotechnol. 92 (2017) 1053–1064, <https://doi.org/10.1002/jctb.5081>.